Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world outcomes with CAR T-cell therapy for secondary central nervous system lymphoma are similar between patients with active versus historical involvement

View Full Paper
Ask AI
Bookmark
Share

Authors

SIShafqat InamAJAnthony JeffreyMDMichael H. Dickinson

Discussion

Loading...

Member takes

Overview

Observational analysis showed response rates comparable in patients with active versus historical sCNSL, suggesting effective CAR T-cell therapy.

Key Points

  • Patients with secondary central nervous system lymphoma exhibited favorable outcomes after CAR T-cell therapy.
  • The overall response rate was 82% with a median follow-up of 11.2 months, highlighting CAR T-cell therapy's efficacy.
  • Data from six centers contributed to insights on cytokine release syndrome and immune-related toxicities in this population.
  • Findings highlight the importance of continuing to study CAR T-cell therapy for better understanding and treatment strategies.

Cite This Study

Inam et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d59ahttps://doi.org/10.1182/blood-2025-1936
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A simple scoring system for response and toxicity following lymphoma CAR-T: Results from the Australian CAR-T real-world consortium2025 · 1 citations
  2. 2CAR T-cell therapy in secondary CNS lymphomas: A real-world study from the descar-t registry2025
  3. 3Real world chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma: The Australian experience2025
  4. 4Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma2025 · 21 citations
  5. 5Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors2025